Skip to main content
Clinical Trials/NCT00056173
NCT00056173CompletedPhase 1

A Phase I/II Study of GTI-2040 and Capecitabine Combination Therapy in Patients With Advanced or Metastatic Renal Cell Carcinoma (mRCC)

Aptose Biosciences Inc.20 sites in 1 country43 target enrollmentStarted: March 2002Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
43
Locations
20

Study Overview

Brief Summary

This phase II, 43 patient trial, will evaluate the efficacy of GTI-2040, an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase (RNR) mRNA, in combination with capecitabine, in the setting of advanced/metastatic renal cell carcinoma. Preclinical studies have shown synergy between GTI-2040 and capecitabine against renal cell carcinoma.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry

Study Sites (20)

Loading locations...

Similar Trials

Completed
Phase 2
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerMale Breast Cancer
NCT00068588National Cancer Institute (NCI)24
Completed
Phase 1
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromesUntreated Adult Acute Lymphoblastic LeukemiaUntreated Adult Acute Myeloid LeukemiaAcute Undifferentiated Leukemia
NCT00459212National Cancer Institute (NCI)24
Completed
Phase 1
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid Leukemia
NCT00070551National Cancer Institute (NCI)51
Completed
Phase 1
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid TumorsRecurrent Colon CancerRecurrent Rectal CancerStage IIIC Colon CancerStage IIIC Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal CancerUnspecified Adult Solid Tumor, Protocol Specific
NCT00084643National Cancer Institute (NCI)20
Completed
Phase 1
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid TumorsUnspecified Adult Solid Tumor, Protocol Specific
NCT00078962National Cancer Institute (NCI)40
Combination of Capecitabine and GTI-2040... | Clinical Trial